This Pearl is provided as free content subject to our terms and conditions click here
Quinolones (the -floxacins): the risks
Quinolones (the -floxacins): the risks
Systemic fluoroquinolones must only be prescribed when other antibiotics commonly recommended for that infection are inappropriate (MHRA drug safety update 2024). |
This article was updated in January 2024.
There have been longstanding concerns about the safety of fluoroquinolones, and advice from both the European Medicines Agency and the MHRA to restrict prescribing has been in place since 2018 (EMA Pharmacovigilance Risk Assessment Committee 2018, MHRA 2018).
In January 2024, the MHRA updated its guidance to introduce further limitations on the prescribing of fluoroquinolones (MHRA 2024).
The antibiotics involved
In the UK, five fluoroquinolones are available:
- Ciprofloxacin.
- Levofloxacin.
- Moxifloxacin.
- Norfloxacin.
- Ofloxacin.
The warning
Systemic (taken by mouth, inhalation or injection) fluoroquinolones can cause long-lasting, potentially irreversible or disabling side-effects which can affect multiple body systems and senses.
Systemic fluoroquinolones must only be used when:
- There is resistance to other first-line antibiotics recommended for the infection.
- Other first-line antibiotics are contraindicated in an individual patient.
- Other first-line antibiotics have caused side-effects in the patient that require treatment to be stopped.
- Treatment with other first-line antibiotics has failed.
This advice is in addition to previous MHRA recommendations that fluoroquinolones should not be prescribed for non-severe or self-limiting infections, or for non-bacterial conditions (MHRA 2018). Fluoroquinolones should not be used to prevent traveller’s diarrhoea, treat recurrent lower urinary tract infections, or treat people who have had previous serious side-effects from quinolones (EMA 2018).
Use particular caution in those with higher risk of tendon injury (MHRA 2023):
The risks and what to look out for
Symptoms/risk groups | Action (and reference) | |
Musculoskeletal system | This includes: | (EMA October 2018) |
Neurological symptoms | This includes: | |
Aortic aneurysm and dissection | Those who may be at particular risk (and, remember, these risks are greater in the elderly in whom special care should be taken): | (MHRA Nov 2018) |
Seizures | ||
Mental health |
And don’t forget to report any of the symptoms on a Yellow Card!
How great is the risk?
For aortic aneurysm/dissection, the EMA suggests that the increased risk is small:
- 82 extra cases/million patients treated in the first 60 days after treatment (when compared with amoxicillin use).
- That is a small number but is against a background rate of about 30–300 cases/million people/year in the general population.
When does the risk occur?
- Tendon rupture has been reported within 48 hours of treatment, and the risk of rupture remains high for months after quinolone treatment.
- Aneurysm/dissections have been noted to be a risk for at least 60 days after treatment.
Quinolones: the risks | |
Audit your prescribing to see: |
This information is for use by clinicians for individual educational purposes, and should be used only within the context of the scope of your personal practice. It should not be shared or used for commercial purposes. If you wish to use our content for group or commercial purposes, you must contact us at sales@red-whale.co.uk to discuss licensing, otherwise you may be infringing our intellectual property rights.
Although we make reasonable efforts to update and check the information in our content is accurate at the date of publication or presentation, we make no representations, warranties or guarantees, whether express or implied, that the information in our products is accurate, complete or up to date.
This content is, of necessity, of a brief and general nature, and this should not replace your own good clinical judgment or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular, check drug doses, side effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in these pages.
For access to our full terms and conditions click here